Recruiting • Phase NA • Stage III, IV • HER2 negative • Post-Menopausal • Non-interventional
The following is imported from ClinicalTrials.gov:
ACT-MBC prospectively assesses the impact of CTCs on treatment decisions, response assessment and prognosis in MBC patients.
Breast Cancer
Observational
65 participant
December 12, 2022
18 - 999
both
CellSearch Circulating Tumor Cells
invasive breast cancer with radiographic and/or clinical evidence of advanced metastatic or unresectable disease
er+/her2- patients prior to starting 2nd line therapy or beyond or er/progesterone receptor (pr)/her2-negative (triple negative) patients prior to starting any line of therapy
measurable and/or non-measurable disease is allowed
male or female breast cancer is allowed
age > 18 years
willingness to provide mandatory blood specimens
willing to return to enrolling institution for follow up imaging at least once
life expectancy of ≤ 6 months
inability to provide blood samples based on the judgment of the treating provider
Recruiting
65
03/22/2024
Menarini Silicon Biosystems, INC
Rochester, Minnesota, United States
Eau Claire, Wisconsin, United States
Mayo Clinic Health System Albert Lea
Albert Lea, Minnesota, United States
Mayo Clinic Health System Mankato
Mankato, Minnesota, United States
© 2024 Outcomes4Me Inc. All rights reserved.